Melanoma (Skin)SAFESTNCT05982600
Safety and Avoidance of Futile Excisions Through Skin Tele-triage
An observational study of Melanoma (Skin) and Telemedicine, run by Herlev Hospital at 1 site in Denmark.
Trial summary
The goal of this study is to estimate the triage values, efficiency and safety of tele-dermoscopic triage of skin lesions suspected of melanoma. The main question[s] it aims to answer are: What is the rate of correct patient management by a single, 2, 3 and 5 dermatologists. Read more about this study
- Who is it for?
- Ages 18 to 80 yearsHealthy volunteers can take part
- Conditions the study is for
- Melanoma (Skin), Telemedicine
- What is being tested?
- Single Assessor Teledermatological triage (TDT), 2 people Teledermatological triage (TDT) and 3 people Teledermatological triage (TDT)
- How many people
- 5 participants
- Where
- 1 siteDenmark
- Study dates
- 1 Sep 2023to 24 Apr 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: 250 retrospectively randomly selected patients referred to the Department of Plastic Surgery at Herlev Hospital because of suspicion of melanoma in the period between May 1st and December 31st 2022.
Who may be able to join
- Referred to the Department of Plastic Surgery at Herlev Hospital because of suspicion of melanoma
- Clinical and dermoscopic images registered in Dermloop
- Histopathological diagnosis available for the lesion
Who cannot join
- The patient's images cannot be anonymized adequately
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Effect of Teledermoscopic Triage on Clinical Management of Skin Lesions Suspected of Melanoma
The goal of this study is to estimate the triage values, efficiency and safety of tele-dermoscopic triage of skin lesions suspected of melanoma. The main question[s] it aims to answer are:
- What is the rate of correct patient management by a single, 2, 3 and 5 dermatologists.
- What is the consequence for the patients if teledermoscopic triage is implemented, in termes of missed melanomas and reduced unnecessary excisions/biopsies.
Read more
Retrospectively included patients will have their skin lesions re-examined by setups of 1, 2, 3 and 5 tele-dermoscopists who will assign a tentative diagnosis and a recommended clinical action.
The investigators will compare the rate of correct patient management between the different setups.
Read the detailed description
Background The incidence of melanoma has been increasing in Denmark for decades [1]. With an age-standardized rate of 29.7 per 100.000 citizens, Denmark has the third highest melanoma rate in the world, and the highest rate for women (33.6) [2].
The excision rate in Danish departments of plastic surgery is close to 100%, although only 46% of referred patients have a malignant tumour [3].
To combat this over-treatment, the patient should be triaged by an expert in evaluation of skin tumours as early as possible, who, to a higher degree, could be able to distinguish between benign and malignant skin lesions and dismiss patients with benign lesions without a biopsy.
This triage should therefore be made by subspecialized dermatologists with expertise regarding diagnosing melanocytic skin lesions.
Teledermoscopy has a high sensitivity equal to face-to-face examination [8], and images taken in the primary care setting and at the hospital have been found to be of comparable quality [9], enabling an accurate assessment of images acquired in the primary care setting.
Our hypothesis is that a mandatory teledermoscopic triage by teledermoscopic experts for all pigmented lesions referred for excision, may reduce the number of unnecessary benign excisions. Yet even the experts may misdiagnose these tricky lesions, and so this study aims to evaluate the management and diagnostic values of a teledermoscopic expert panel on a high-incidence dataset and the safety of the triage method before potential clinical implementation.
Methods Based on a sample size calculation (see Statistics), 250 consecutive patients from the dataset will be included. The patients, whose skin lesions are included in the study, have been referred from PCPs or departments of dermatology at the local public hospitals, but the majority were referred by privately practicing dermatologists.
The teledermatological experts included in this study are dermatologists working mainly with diagnosing melanoma, who have more than 10 years of clinical dermatology experience and have clinical experience with teledermoscopy of melanocytic skin lesions.
Patient and lesion data and images are obtained from the electronic medical record systems Dermloop (Melatech ApS) and Sundhedsplatformen (Epic Systems), used at the Department of Plastic Surgery, Herlev and Gentofte Hospital.
The panel of tele-dermatologists will review all cases and determine a diagnosis and a management. To be able to distinguish primary and secondary outcomes, both a diagnosis and recommended clinical management are required from the experts.
Outcomes The primary outcome of the study is the recommended clinical management, Triage Values, of the TDT panels. The recommended clinical management for each lesion is assessed in binary classification of correct vs incorrect by a list of pre-defined "best practice management" rules based on its histopathological diagnosis outlined in Table 3.
Both a Majority Consensus and a Worst-Case analysis (see Statistics for further explanation) will be done.
In addition, the investigators will report the number of each management option recommended by the different modes of tele-dermatological assessment (single assessor, 2, 3 and 5 assessors).
Secondary outcomes include assessing the diagnostic values (in terms of Sensitivity, Specificity, False Negative and False Positive Rate using the dichotomized histopathological diagnosis of benign vs malignant as Gold Standard) of the TDT expert panel.
The diagnostic accuracy and range are reported separately. For the melanomas in the dataset, a descriptive analysis will me made of how often the tele-dermatologists correctly identify the Breslow thickness, in terms of true positives for each category.
Statistical analysis and Sample Size Calculation In order to discern a disparity between the conventional practice and the diagnostic efficacy of teledermatological assessment, a sample size of 44 cases is sufficient to detect a statistically significant difference, with a level of significance set at 0.05, accompanied by a statistical power of 80%. However, when evaluating the safety of a pure teledermatological triage system, it is imperative to ensure a sufficiently high sensitivity to avoid overlooking melanomas, while concurrently achieving a narrow confidence interval to confidently articulate the findings.
Based on a simulation model using R Studio [16] of five teledermoscopy experts diagnosing a number of cases with a 40% prevalence of malignancy with a sensitivity and specificity estimated from previous studies [8, 17] an estimated sensitivity of 99% can be found with a narrow confidence interval from 99%-100% with five experts evaluating 250 patient cases. Choosing an uneven number of experts for the panel enables a Majority Consensus analysis and easier interpretation of the results in regard to clinical practice.
Management is ranked hierarchically when defining "worst case" as follows, from least to worst: Dismiss, Dermatological Treatment, Followup, Biopsy, Excision.
Because incongruence between the experts is inevitable, separate analyses will be made using 1) majority consensus (ignoring answers given by less than half of the panel) and 2) "worst-case" consensus (letting even a single expert's suspicion of malignancy or recommendation for a management of a higher rank overrule the rest of the panel).
Perspective This study will report the number of patients that could have avoided having their skin lesions excised and to what degree malignant skin lesions would have been incorrectly managed if the teledermoscopically recommended clinical management had been followed.
The knowledge gained from this study has the potential to significantly change how to diagnose and triage patients suspected of having melanoma, which is the most common type of cancer among young Danes aged 15-34 [18].
The results of this and future studies will lead to the excision and treatment of fewer benign skin lesions and pave the way for a smoother patient pathway with less physical referrals, which will benefit not only patients but also lead to potential savings for the healthcare system resources by reducing the number of unnecessary consultations and procedures.
- Conditions
- Melanoma (Skin), Telemedicine
- Being tested
- Single Assessor Teledermatological triage (TDT), 2 people Teledermatological triage (TDT), 3 people Teledermatological triage (TDT), 5 people Teledermatological triage (TDT)
- Keywords
- Teledermoscopy, Melanoma, Pigmented Skin Lesions, Telemedicine
- Medical subject headings
- Melanoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Single Assessor Teledermatological triage (TDT)Diagnostic test
Also called Single Assessor
The skin lesion is assessed, diagnosed and triaged by one dermatologist assessors.
2 people Teledermatological triage (TDT)Diagnostic test
Also called 2 people assessment
The skin lesion is assessed, diagnosed and triaged by 2 dermatologist assessors. Worst case overrules.
3 people Teledermatological triage (TDT)Diagnostic test
Also called 3 people assessment
The skin lesion is assessed, diagnosed and triaged by 3 dermatologist assessors. Worst case and majority consensus assessments are calculated separately.
5 people Teledermatological triage (TDT)Diagnostic test
Also called 5 people assessment
The skin lesion is assessed, diagnosed and triaged by 5 dermatologist assessors. Worst case and majority consensus assessments are calculated separately.
| Study group | Role | What they receive |
|---|---|---|
| Cancer Pathway referred patient | Patient referred for assessment and excision of their skin lesion, because of a suspicion of melanoma by the referring doctor. Receives: Diagnostic Test: Single Assessor Teledermatological triage (TDT); Diagnostic Test: 2 people Teledermatological triage (TDT); Diagnostic Test: 3 people Teledermatological triage (TDT); Diagnostic Test: 5 people Teledermatological triage (TDT) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Triage Values
Recommended clinical action, correct vs incorrect. Each teledermatologist will recommend a clinical action for each patient case. We evaluate the correctness of this recommended clinical action (in binary classification of correct vs incorrect) by a list of pre-defined "best practice management rules" for each diagnosis.
Measured: Immediately after all participants have completed the evaluations
Secondary outcomes (1)
Diagnostic Values
Secondary outcomes include assessing the diagnostic values (in terms of Sensitivity, Specificity, False Negative and False Positive Rate using the dichotomized histopathological diagnosis of benign vs malignant as Gold Standard) of the TDT expert panel.
Measured: Immediately after all participants have completed the evaluations
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Aug 2023
- Study start1 Sep 2023
- Primary completion31 Dec 2023
- Study completion24 Apr 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Melanoma (Skin)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 5 participants (actual)
Sponsor and investigators
- Lead sponsor
- Herlev Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Gustav Gede Nervil, Herlev Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05982600
- Sponsor's protocol ID
- SAFEST Trial
- Acronym
- SAFEST
- Status last verified
- Oct 2024
- First submitted
- 24 Jul 2023
- Last updated
- 8 Oct 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Sample-size simulation codes, data-analysis codes and deidentified data will be shared through data repository.
Study at a glance
From the registry record, last updated by the sponsor on 8 Oct 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Teledermoscopic Triage on Clinical Management of Skin Lesions Suspected of Melanoma
- ClinicalTrials.gov ID
- NCT05982600
- Acronym / sponsor ID
- SAFEST / SAFEST Trial
- Conditions
- Melanoma (Skin), Telemedicine
- Keywords
- Teledermoscopy, Melanoma, Pigmented Skin Lesions, Telemedicine
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 5 participants (actual)
- Lead sponsor
- Herlev HospitalUniversity, hospital or other
- Study start
- 1 Sep 2023 (actual)
- Primary completion
- 31 Dec 2023 (actual)
- Study completion
- 24 Apr 2024 (actual)
- First posted
- 8 Aug 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this study is to estimate the triage values, efficiency and safety of tele-dermoscopic triage of skin lesions suspected of melanoma. The main question[s] it aims to answer are:
- What is the rate of correct patient management by a single, 2, 3 and 5 dermatologists.
- What is the consequence for the patients if teledermoscopic triage is implemented, in termes of missed melanomas and reduced unnecessary excisions/biopsies.
Retrospectively included patients will have their skin lesions re-examined by setups of 1, 2, 3 and 5 tele-dermoscopists who will assign a tentative diagnosis and a recommended clinical action.
The investigators will compare the rate of correct patient management between the different setups.
Detailed description
Background The incidence of melanoma has been increasing in Denmark for decades [1]. With an age-standardized rate of 29.7 per 100.000 citizens, Denmark has the third highest melanoma rate in the world, and the highest rate for women (33.6) [2].
The excision rate in Danish departments of plastic surgery is close to 100%, although only 46% of referred patients have a malignant tumour [3].
To combat this over-treatment, the patient should be triaged by an expert in evaluation of skin tumours as early as possible, who, to a higher degree, could be able to distinguish between benign and malignant skin lesions and dismiss patients with benign lesions without a biopsy.
This triage should therefore be made by subspecialized dermatologists with expertise regarding diagnosing melanocytic skin lesions.
Teledermoscopy has a high sensitivity equal to face-to-face examination [8], and images taken in the primary care setting and at the hospital have been found to be of comparable quality [9], enabling an accurate assessment of images acquired in the primary care setting.
Our hypothesis is that a mandatory teledermoscopic triage by teledermoscopic experts for all pigmented lesions referred for excision, may reduce the number of unnecessary benign excisions. Yet even the experts may misdiagnose these tricky lesions, and so this study aims to evaluate the management and diagnostic values of a teledermoscopic expert panel on a high-incidence dataset and the safety of the triage method before potential clinical implementation.
Methods Based on a sample size calculation (see Statistics), 250 consecutive patients from the dataset will be included. The patients, whose skin lesions are included in the study, have been referred from PCPs or departments of dermatology at the local public hospitals, but the majority were referred by privately practicing dermatologists.
The teledermatological experts included in this study are dermatologists working mainly with diagnosing melanoma, who have more than 10 years of clinical dermatology experience and have clinical experience with teledermoscopy of melanocytic skin lesions.
Patient and lesion data and images are obtained from the electronic medical record systems Dermloop (Melatech ApS) and Sundhedsplatformen (Epic Systems), used at the Department of Plastic Surgery, Herlev and Gentofte Hospital.
The panel of tele-dermatologists will review all cases and determine a diagnosis and a management. To be able to distinguish primary and secondary outcomes, both a diagnosis and recommended clinical management are required from the experts.
Outcomes The primary outcome of the study is the recommended clinical management, Triage Values, of the TDT panels. The recommended clinical management for each lesion is assessed in binary classification of correct vs incorrect by a list of pre-defined "best practice management" rules based on its histopathological diagnosis outlined in Table 3.
Both a Majority Consensus and a Worst-Case analysis (see Statistics for further explanation) will be done.
In addition, the investigators will report the number of each management option recommended by the different modes of tele-dermatological assessment (single assessor, 2, 3 and 5 assessors).
Secondary outcomes include assessing the diagnostic values (in terms of Sensitivity, Specificity, False Negative and False Positive Rate using the dichotomized histopathological diagnosis of benign vs malignant as Gold Standard) of the TDT expert panel.
The diagnostic accuracy and range are reported separately. For the melanomas in the dataset, a descriptive analysis will me made of how often the tele-dermatologists correctly identify the Breslow thickness, in terms of true positives for each category.
Statistical analysis and Sample Size Calculation In order to discern a disparity between the conventional practice and the diagnostic efficacy of teledermatological assessment, a sample size of 44 cases is sufficient to detect a statistically significant difference, with a level of significance set at 0.05, accompanied by a statistical power of 80%. However, when evaluating the safety of a pure teledermatological triage system, it is imperative to ensure a sufficiently high sensitivity to avoid overlooking melanomas, while concurrently achieving a narrow confidence interval to confidently articulate the findings.
Based on a simulation model using R Studio [16] of five teledermoscopy experts diagnosing a number of cases with a 40% prevalence of malignancy with a sensitivity and specificity estimated from previous studies [8, 17] an estimated sensitivity of 99% can be found with a narrow confidence interval from 99%-100% with five experts evaluating 250 patient cases. Choosing an uneven number of experts for the panel enables a Majority Consensus analysis and easier interpretation of the results in regard to clinical practice.
Management is ranked hierarchically when defining "worst case" as follows, from least to worst: Dismiss, Dermatological Treatment, Followup, Biopsy, Excision.
Because incongruence between the experts is inevitable, separate analyses will be made using 1) majority consensus (ignoring answers given by less than half of the panel) and 2) "worst-case" consensus (letting even a single expert's suspicion of malignancy or recommendation for a management of a higher rank overrule the rest of the panel).
Perspective This study will report the number of patients that could have avoided having their skin lesions excised and to what degree malignant skin lesions would have been incorrectly managed if the teledermoscopically recommended clinical management had been followed.
The knowledge gained from this study has the potential to significantly change how to diagnose and triage patients suspected of having melanoma, which is the most common type of cancer among young Danes aged 15-34 [18].
The results of this and future studies will lead to the excision and treatment of fewer benign skin lesions and pave the way for a smoother patient pathway with less physical referrals, which will benefit not only patients but also lead to potential savings for the healthcare system resources by reducing the number of unnecessary consultations and procedures.
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Cancer Pathway referred patient | – | Diagnostic Test: Single Assessor Teledermatological triage (TDT), Diagnostic Test: 2 people Teledermatological triage (TDT), Diagnostic Test: 3 people Teledermatological triage (TDT), Diagnostic Test: 5 people Teledermatological triage (TDT)Patient referred for assessment and excision of their skin lesion, because of a suspicion of melanoma by the referring doctor. |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- 250 retrospectively randomly selected patients referred to the Department of Plastic Surgery at Herlev Hospital because of suspicion of melanoma in the period between May 1st and December 31st 2022.
Key inclusion criteria (3 listed)
- Referred to the Department of Plastic Surgery at Herlev Hospital because of suspicion of melanoma
- Clinical and dermoscopic images registered in Dermloop
- Histopathological diagnosis available for the lesion
Key exclusion criteria (1 listed)
- The patient's images cannot be anonymized adequately
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Single Assessor Teledermatological triage (TDT)Also: Single AssessorThe skin lesion is assessed, diagnosed and triaged by one dermatologist assessors. | Diagnostic test | Cancer Pathway referred patient |
| 2 people Teledermatological triage (TDT)Also: 2 people assessmentThe skin lesion is assessed, diagnosed and triaged by 2 dermatologist assessors. Worst case overrules. | Diagnostic test | Cancer Pathway referred patient |
| 3 people Teledermatological triage (TDT)Also: 3 people assessmentThe skin lesion is assessed, diagnosed and triaged by 3 dermatologist assessors. Worst case and majority consensus assessments are calculated separately. | Diagnostic test | Cancer Pathway referred patient |
| 5 people Teledermatological triage (TDT)Also: 5 people assessmentThe skin lesion is assessed, diagnosed and triaged by 5 dermatologist assessors. Worst case and majority consensus assessments are calculated separately. | Diagnostic test | Cancer Pathway referred patient |
Primary outcome
Triage Values
Time frame: Immediately after all participants have completed the evaluations
Recommended clinical action, correct vs incorrect. Each teledermatologist will recommend a clinical action for each patient case. We evaluate the correctness of this recommended clinical action (in binary classification of correct vs incorrect) by a list of pre-defined "best practice management rules" for each diagnosis.
1 secondary outcome
Diagnostic Values
Time frame: Immediately after all participants have completed the evaluations
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Oct 2024.
- Individual participant dataSharing planned: Yes. Sample-size simulation codes, data-analysis codes and deidentified data will be shared through data repository.
Related trials for Melanoma (Skin)
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingPhase 1
IL-17 Blockade to Decrease irAEs (REPLAY)
Metastatic Melanoma
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
RecruitingPhase 1
A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy
Melanoma
Active, not recruitingPhase 1/2
A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma
Melanoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Melanoma (Skin) and Telemedicine, run by Herlev Hospital at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Triage Values (time frame: Immediately after all participants have completed the evaluations). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Oct 2024.